^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Microtubule inhibitor

    Related drugs:
    1m
    Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study. (PubMed, Front Immunol)
    Adjuvant ADC+ICI showed comparable short-term OS and directionally favorable DFS/PFS trends versus GC, with a distinct toxicity profile. These findings are hypothesis-generating and require prospective validation.
    Clinical • Observational data • Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    cisplatin • gemcitabine • Aidixi (disitamab vedotin)
    1m
    CW-301 FIH Study of CAN016 (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Canwell Biotech Limited | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 mutation • HER-2 expression
    1m
    Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers. (PubMed, Antib Ther)
    A high-affinity anti-CDH17 monoclonal antibody (TAVO307) was generated and conjugated with auristatin-derived cytotoxic payloads to obtain CDH17-directed antibody-drug conjugates (ADCs)...Both CDH17-targeted ADCs and γδ TCEs demonstrated promising potency and efficacy to control GI cancers. They could offer complementary therapeutic options that could be used in combination therapy.
    Journal • IO biomarker
    |
    IL15 (Interleukin 15) • CDH17 (Cadherin 17)
    1m
    POLAREAL: A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=1000, Recruiting, Hoffmann-La Roche | Active, not recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Polivy (polatuzumab vedotin-piiq)
    1m
    DREAMM 12: A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, GlaxoSmithKline | Trial completion date: Dec 2025 --> Mar 2027
    Trial completion date
    |
    Blenrep (belantamab mafodotin-blmf)
    1m
    PYX-201-101: A Study of PYX-201 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=330, Recruiting, Pyxis Oncology, Inc | Trial completion date: May 2027 --> Jun 2028 | Trial primary completion date: Jul 2026 --> Apr 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    micvotabart pelidotin (PYX-201)
    1m
    Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) (clinicaltrials.gov)
    P1/2, N=12, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Polivy (polatuzumab vedotin-piiq)
    1m
    Topographical and stage-related expression of nectin-4 in prostate cancer. (PubMed, Cent European J Urol)
    Nectin-4 expression in the prostate is heterogeneous and context-dependent, with higher levels in benign glands within cancer-bearing prostates and lower levels with advancing tumor stage and nodal/metastatic spread. These findings provide an expression map of nectin 4 across benign and malignant prostate compartments and disease stages and may inform future exploratory enrichment strategies for nectin-4-targeted therapies.
    Journal
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Padcev (enfortumab vedotin-ejfv)
    1m
    Prostate Cancer: Etiology, Diagnosis, and Treatment. (PubMed, Serican J Med)
    For castration-resistant prostate cancer, cabazitaxel and second-generation androgen receptor inhibitors are the major therapeutic approaches. We also review several non-canonical treatment strategies.
    Journal
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • AURKA (Aurora kinase A) • SPOP (Speckle Type BTB/POZ Protein) • FOXA1 (Forkhead Box A1)
    |
    cabazitaxel
    1m
    Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab. (PubMed, Eur Urol Oncol)
    Personalized, tumor-informed ctDNA testing can indicate response to EV±P and is prognostic of survival benefit in patients with la/mUC receiving EV±P.
    Journal • PD(L)-1 Biomarker • Circulating tumor DNA
    |
    Signatera™
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    1m
    MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, Dongguan People's Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Loqtorzi (toripalimab-tpzi) • Meiyouheng (becotatug vedotin)
    1m
    A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma (clinicaltrials.gov)
    P=N/A, N=1000, Completed, Takeda | Active, not recruiting --> Completed
    Trial completion
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive • TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin)